Cogent Biosciences, INC Schedule 13G passive stakes

Vanguard Capital Management reports beneficial ownership of over 8.69 million shares, representing 5.08% of Cogent Biosciences' common stock.

Deerfield Management and James E. Flynn have filed a Schedule 13G reporting a 5.29% beneficial ownership stake in Cogent Biosciences, Inc.

The Vanguard Group reported its beneficial ownership in Cogent Biosciences Inc. has dropped to 0% following an internal corporate realignment.

Kynam Capital Management and affiliates reported a 4.33% beneficial ownership stake in Cogent Biosciences, Inc. common stock as of December 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 7.5% beneficial ownership stake in Cogent Biosciences Inc. as of December 31, 2025.

BlackRock, Inc. has increased its beneficial ownership in Cogent Biosciences, Inc. to 6.5% of common stock, holding over 11.3 million shares.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 6.5% beneficial ownership stake in Cogent Biosciences, Inc. as of December 31, 2025.

Commodore Capital LP and its affiliates have reported a 7.2% beneficial ownership stake in Cogent Biosciences, Inc., totaling 10,208,060 shares.

Paradigm BioCapital Advisors LP and related entities have reported a 2.3% beneficial ownership stake in Cogent Biosciences, Inc. as of September 30, 2025.

TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu have filed an amendment to their Schedule 13G, reporting a beneficial ownership of 4.8% in Cogent Biosciences, Inc.

Point72 Asset Management and its affiliates reported a reduced beneficial ownership stake of 4.0% in Cogent Biosciences, Inc., including convertible preferred stock.

Kynam Capital Management, LP, along with its GP and Yue Tang, has disclosed a beneficial ownership of 5.54% in Cogent Biosciences, Inc. common stock.

Paradigm BioCapital Advisors LP and related entities have reported a 9.1% beneficial ownership stake in Cogent Biosciences, Inc. common stock.

A group of Venrock Healthcare Capital Partners entities and individuals have reduced their beneficial ownership in Cogent Biosciences, Inc. to 4.2% of common stock.

Commodore Capital and its affiliates have reported a 5.5% passive ownership stake in Cogent Biosciences, Inc., totaling 6,408,060 shares.

Commodore Capital LP and Commodore Capital Master LP have reduced their beneficial ownership in Cogent Biosciences, Inc. to 4.6% of common stock.

Deerfield Management and its affiliated entities have disclosed a beneficial ownership of 6.49% in Cogent Biosciences, Inc., totaling 9,053,118 shares of common stock.

Paradigm BioCapital Advisors LP, along with its affiliates, has disclosed a beneficial ownership of 7.9% of Cogent Biosciences, Inc.'s common stock as of March 31, 2025.

Venrock Healthcare Capital Partners has filed an amended Schedule 13G for Cogent Biosciences, Inc., correcting a clerical error that previously overstated their beneficial ownership to 5.8% as of September 30, 2024.

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported a beneficial ownership of 8.7% in Cogent Biosciences, Inc. as of December 31, 2024.

Paradigm BioCapital Advisors LP and its affiliates have reported a 5.0% beneficial ownership stake in Cogent Biosciences, Inc., signaling a passive investment.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a combined beneficial ownership of 15.0% of Cogent Biosciences Inc.'s common stock as of December 31, 2024.